Neratinib, fulvestrant and trastuzumab in HER2-mutant metastatic breast cancer
The SUMMIT study shows that the combination of neratinib, fulvestrant and trastuzumab is effective in HER2-mutant metastatic breast cancer after progression on CDK4/6 inhibitors